Monday, January 03, 2022 4:35:15 PM
GNPX was 7 dollars this time last year, I don't see how that investment has paid anyone off?
Just some who will lie about how they bought this last week and predicted today?
But everyone knows from posting history, they didn't?
IMO
Everything I post, is In my own opinion, I don't care what you think about it, if you disagree, post it like I do. If you buy or sell stock based on what I say, your a lunatic and should not be trading. Have a great day!
Recent GNPX News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/08/2024 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 02:29:40 PM
- Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting • PR Newswire (US) • 11/05/2024 02:29:00 PM
- Genprex to Participate in 2024 BIO Europe Conference • PR Newswire (US) • 10/31/2024 01:29:00 PM
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma • PR Newswire (US) • 10/28/2024 01:29:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/24/2024 04:23:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 01:29:33 PM
- Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive • PR Newswire (US) • 10/24/2024 01:29:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/22/2024 04:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 01:29:57 PM
- Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer • PR Newswire (US) • 10/15/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics • PR Newswire (US) • 10/10/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting • PR Newswire (US) • 10/07/2024 01:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2024 09:15:33 PM
- Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes • PR Newswire (US) • 09/23/2024 01:29:00 PM
- Genprex Announces Formation of Mesothelioma Clinical Advisory Board • PR Newswire (US) • 09/19/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics • PR Newswire (US) • 09/09/2024 01:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 01:30:39 PM
- Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes • PR Newswire (US) • 09/04/2024 01:29:00 PM
- Genprex to Present and Participate at Upcoming September Investor and Industry Conferences • PR Newswire (US) • 09/03/2024 12:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:18:55 PM
- Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials • PR Newswire (US) • 08/15/2024 01:30:00 PM
- Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer • PR Newswire (US) • 08/14/2024 01:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:38:12 PM
- Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers • PR Newswire (US) • 08/13/2024 12:31:00 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM